Compare MPTI & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPTI | ASMB |
|---|---|---|
| Founded | 1965 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.9M | 442.9M |
| IPO Year | 2022 | 2010 |
| Metric | MPTI | ASMB |
|---|---|---|
| Price | $77.24 | $27.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $71.00 | $44.20 |
| AVG Volume (30 Days) | 65.0K | ★ 111.1K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ 0.67 | N/A |
| Revenue | ★ $54,417,000.00 | N/A |
| Revenue This Year | $11.06 | N/A |
| Revenue Next Year | $12.15 | $638.39 |
| P/E Ratio | $117.52 | ★ N/A |
| Revenue Growth | ★ 11.03 | N/A |
| 52 Week Low | $36.38 | $13.13 |
| 52 Week High | $87.23 | $39.71 |
| Indicator | MPTI | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 59.94 | 43.20 |
| Support Level | $60.13 | $26.50 |
| Resistance Level | $79.58 | $30.58 |
| Average True Range (ATR) | 4.68 | 1.75 |
| MACD | 0.78 | -0.06 |
| Stochastic Oscillator | 59.37 | 25.12 |
M-Tron Industries Inc is an electronic components manufacturer based in the United States. Along with its subsidiaries, the company is engaged in designing, manufacturing, and marketing high-engineered, high-reliability frequency and spectrum control products used to control the frequency or timing of signals in electronic circuits in various applications. The company serves markets in aerospace and defense, space, and avionics sectors. Its product offerings include microwave and millimeter-wave filters, crystal resonators, clock oscillators, voltage-controlled crystal oscillators, low noise amplifiers, couplers, attenuators, and switches, among others. Geographically, it derives maximum revenue from the domestic market, and the rest from Malaysia, Australia, Greece, and other countries.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.